Novo Nordisk A/S buy HOPY96
Summary
This prediction ended on 03.02.14 with a price of €29.20. The prediction had a final performance of 18.17%. HOPY96 has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novo Nordisk A/S | - | - | - | - |
| iShares Core DAX® | -2.023% | -3.140% | 10.499% | 13.078% |
| iShares Nasdaq 100 | 4.625% | 8.753% | 34.939% | 57.906% |
| iShares Nikkei 225® | -2.088% | -0.980% | 3.292% | 2.524% |
| iShares S&P 500 | 2.398% | 4.677% | 27.998% | 49.604% |
Comments by HOPY96 for this prediction
In the thread Novo Nordisk A/S diskutieren
FDA
Die FDA macht den Zukunftsplänen von Novo Nordisk einen Strich durch die Rechnung.
Die Zulassung für das Diabetikmedikament Tresbia wird verweigert. Die Aktie stürzt ab. Für mich eine Gelegenheit eine gute Aktie ausserhalb des Euroraums auf ermässigtem Niveau kaufen zu können.